Apr. 20, 2017 – GenorBiopharma Co., Ltd.,Shanghai, CHINA
Genor Biopharma has submitted its antibody GB223 IND applicationto Shanghai CFDA, and has been received the Notice of Acceptance of Drugapplication for registration of Shanghai Food and Drug Administration NocticeReference number: CXSL1700041沪、CXSL1700042沪；Application matters: New drug application; Classification: Class 1 ;Therapeutic biological products; Declaration stage: Clinical.
For Detail, Pleasee seeWalvax's (300142) Announcement：2017-036
About Genor BioPharma
Founded in2007, Genor BioPharma Co. Ltd. is aninnovation-driven biopharmaceutical companyfocused on development andcommercialization of therapeutic monoclonalantibodies (mAbs) and Fc-fusionproteins. Genor has more than 10 products in thepipeline, six ofwhich are atIND and clinical stages, including GB221, GB232, GB242,GB222, GB241 and GB224.Genor has approximately 160 employees, and awell-integrated expert andmanagement team with entrenched experience andexpertise from USbiopharmaceutical giants such as Amgen, Genentech, and Abbottetc. Genor hasestablished a 6,000 m2 researchand developmentcenter, which includes R&D and process development labs,analytical andquality center, and a cGMP clinical production facility. Itscommercial-scalecGMP production facility is also under planning. For moreinfo, please visit:www.genorbio.com.